Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Diverse Roles of Anticonvulsants in Bipolar Disorders

The Diverse Roles of Anticonvulsants in Bipolar Disorders Anticonvulsant drugs (ACs) have diverse antiseizure, psychotropic, and biochemical effects. Carbamazepine and valproate have mood-stabilizing actions, benzodiazepines and gabapentin have anxiolytic actions, lamotrigine is useful in rapid cycling and acute treatment and prophylaxis of bipolar depression, and topiramate and zonisamide can yield weight loss. Limited controlled data suggest the carbamazepine keto derivative oxcarbazepine has antimanic effects. A categorical approach to the diverse roles of ACs in bipolar disorders is proposed, using broad categories of ACs, on the basis of their predominant psychotropic profiles. Thus, some ACs have “sedating” profiles that may include sedation, cognitive difficulties, fatigue, weight gain, and possibly antimanic and/or anxiolytic effects. In contrast, some newer ACs have “activating” profiles that may include improved energy, weight loss, and possibly antidepressant and even anxiogenic effects. Still other newer ACs have novel “mixed” profiles, combining sedation and weight loss. A categorical–mechanistic extension of this approach is also presented, with hypotheses that “sedating” profiles might be related to prominent potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, “activating” profiles could be related to prominent attenuation of glutamate excitatory neurotransmission, and for “mixed” profiles, sedation and weight loss might be related to concurrent GABAergic and antiglutamatergic actions, respectively. The categorical approach may have utility as an aid to clinicians in reinforcing the heterogeneity ACs, and recalling psychotropic profiles of individual ACs, but is limited as it fails to address the etiology of the heterogeneity of AC psychotropic effects. The categorical–mechanistic extension strives to address this issue, but requires systematic clinical investigation of more precise relationships between psychotropic profiles and discrete mechanisms of action to assess its merits. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

The Diverse Roles of Anticonvulsants in Bipolar Disorders

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/the-diverse-roles-of-anticonvulsants-in-bipolar-disorders-MdylCOGVi6
Publisher
Springer Journals
Copyright
Copyright © 2003 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1024636309185
Publisher site
See Article on Publisher Site

Abstract

Anticonvulsant drugs (ACs) have diverse antiseizure, psychotropic, and biochemical effects. Carbamazepine and valproate have mood-stabilizing actions, benzodiazepines and gabapentin have anxiolytic actions, lamotrigine is useful in rapid cycling and acute treatment and prophylaxis of bipolar depression, and topiramate and zonisamide can yield weight loss. Limited controlled data suggest the carbamazepine keto derivative oxcarbazepine has antimanic effects. A categorical approach to the diverse roles of ACs in bipolar disorders is proposed, using broad categories of ACs, on the basis of their predominant psychotropic profiles. Thus, some ACs have “sedating” profiles that may include sedation, cognitive difficulties, fatigue, weight gain, and possibly antimanic and/or anxiolytic effects. In contrast, some newer ACs have “activating” profiles that may include improved energy, weight loss, and possibly antidepressant and even anxiogenic effects. Still other newer ACs have novel “mixed” profiles, combining sedation and weight loss. A categorical–mechanistic extension of this approach is also presented, with hypotheses that “sedating” profiles might be related to prominent potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, “activating” profiles could be related to prominent attenuation of glutamate excitatory neurotransmission, and for “mixed” profiles, sedation and weight loss might be related to concurrent GABAergic and antiglutamatergic actions, respectively. The categorical approach may have utility as an aid to clinicians in reinforcing the heterogeneity ACs, and recalling psychotropic profiles of individual ACs, but is limited as it fails to address the etiology of the heterogeneity of AC psychotropic effects. The categorical–mechanistic extension strives to address this issue, but requires systematic clinical investigation of more precise relationships between psychotropic profiles and discrete mechanisms of action to assess its merits.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 11, 2004

References

  • Predictors of treatment response in bipolar disorder: Evidence from clinical and PET studies.
    Ketter, TA; Kimbrell, TA; George, MS; Sachs, N; Wang, PW; Post, RM
  • Practice guideline for the treatment of patients with bipolar disorder (revision)
  • GABA and mood disorders: A brief review and hypothesis.
    Petty, F
  • GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders?
    Motohashi, N; Ikawa, K; Kariya, T
  • GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate.
    Motohashi, N
  • Lack of beneficial effects of l-baclofen in affective disorder.
    Post, RM; Ketter, TA; Joffe, RT; Kramlinger, KL
  • Valproate in the treatment of acute mania. A placebo-controlled study.
    Pope, HG; McElroy, SL; Keck, PE; Hudson, JI
  • (The Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania.
    Bowden, CL; Brugger, AM; Swann, AC; Calabrese, JR; Janicak, PG; Petty, F; Dilsaver, SC; Davis, JM; Rush, AJ; Small, JG; Garza-Treviño, ES; Risch, SC; Goodnick, PJ; Morris, DD
  • Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression.
    Winsberg, ME; DeGolia, SG; Strong, CM; Ketter, TA
  • Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature.
    Ketter, TA; Calabrese, JR
  • Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone.
    Andersen, T; Lingjaerde, O
  • Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, I: Efficacy in short-term treatment.
    Ballenger, JC; Burrows, GD; DuPont, RL; Lesser, IM; Noyes, R; Pecknold, JC; Rifkin, A; Swinson, RP
  • Treatment of social phobia with gabapentin: A placebo-controlled study.
    Pande, AC; Davidson, JR; Jefferson, JW; Janney, CA; Katzelnick, DJ; Weisler, RH; Greist, JH; Sutherland, SM
  • Placebo-controlled study of gabapentin treatment of panic disorder.
    Pande, AC; Pollack, MH; Crockatt, J; Greiner, M; Chouinard, G; Lydiard, RB; Taylor, CB; Dager, SR; Shiovitz, T
  • Double-blind comparison of the effects of clonazepam and lorazepam in acute mania.
    Bradwejn, J; Shriqui, C; Koszycki, D; Meterissian, G
  • (Gabapentin Bipolar Disorder Study Group): Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy.
    Pande, AC; Crockatt, J; Janney, CA; Werth, JL; Tsaroucha, G
  • Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.
    Rickels, K; Chung, HR; Csanalosi, IB; Hurowitz, AM; London, J; Wiseman, K; Kaplan, M; Amsterdam, JD
  • Gabapentin augmentation therapy in bipolar depression.
    Wang, PW; Santosa, C; Schumacher, M; Winsberg, ME; Strong, C; Ketter, TA
  • Plasma glutamate decarboxylase activity in neuropsychiatry.
    Kaiya, H; Namba, M; Yoshida, H; Nakamura, S
  • Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims.
    Nowak, G; Ordway, GA; Paul, IA
  • Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study.
    Auer, DP; Putz, B; Kraft, E; Lipinski, B; Schill, J; Holsboer, F
  • The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
    Goff, DC; Coyle, JT
  • Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate-and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture.
    Cai, Z; McCaslin, PP
  • Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid.
    Nowak, G; Trullas, R; Layer, RT; Skolnick, P; Paul, IA
  • Effect of lithium and other alkali metals on brain chemistry and behavior, I: Glutamic acid and GABA in brain regions.
    Gottesfeld, Z
  • Acute and short-term effects of lithium on glutamate metabolism in rat brain.
    Marcus, SR; Nadiger, HA; Chandrakala, MV; Rao, TI; Sadasivudu, B
  • A novel action of lithium: Stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices.
    Hokin, LE; Dixon, JF; Los, GV
  • (Lamictal 602 Study Group): A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.
    Calabrese, JR; Bowden, CL; Sachs, GS; Ascher, JA; Monaghan, E; Rudd, GD
  • Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital.
    Twyman, RE; Rogers, CJ; Macdonald, RL
  • Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder.
    MacKinnon, DF; Zandi, PP; Cooper, J; Potash, JB; Simpson, SG; Gershon, E; Nurnberger, J; Reich, T; DePaulo, JR
  • Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons.
    Lampe, H; Bigalke, H
  • Time course of clinical effects of carbamazepine: Implications for mechanisms of action.
    Post, RM
  • Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
    Ambrosio, AF; Soares-Da-Silva, P; Carvalho, CM; Carvalho, AP
  • Antidepressant effects of carbamazepine.
    Post, RM; Uhde, TW; Roy-Byrne, PP; Joffe, RT
  • Lack of efficacy of carbamazepine in the treatment of panic disorder.
    Uhde, TW; Stein, MB; Post, RM
  • (The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group): A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults.
    Mattson, RH; Cramer, JA; Collins, JF
  • The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.
    Rattya, J; Vainionpaa, L; Knip, M; Lanning, P; Isojarvi, JI
  • Principles of clinically important drug interactions with carbamazepine, Part I.
    Ketter, TA; Post, RM; Worthington, K
  • Principles of clinically important drug interactions with carbamazepine, Part II.
    Ketter, TA; Post, RM; Worthington, K
  • Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk.
    Tohen, M; Castillo, J; Baldessarini, RJ; Zarate, C; Kando, JC
  • Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.
    Greil, W; Kleindienst, N; Erazo, N; Muller-Oerlinghausen, B
  • Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action.
    Löscher, W
  • Valproate treatment of panic disorder and lactate-induced panic attacks.
    Keck, PE; Taylor, VE; Tugrul, KC; McElroy, SL; Bennett, JA
  • Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.
    Hirschfeld, RM; Allen, MH; McEvoy, JP; Keck, PE; Russell, JM
  • Relation of serum valproate concentration to response in mania.
    Bowden, CL; Janicak, PG; Orsulak, P; Swann, AC; Davis, JM; Calabrese, JR; Goodnick, P; Small, JG; Rush, AJ; Kimmel, SE; Risch, SC; Morris, DD
  • (Divalproex Maintenance Study Group): A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder.
    Bowden, CL; Calabrese, JR; McElroy, SL; Gyulai, L; Wassef, A; Petty, F; Pope, HG; Chou, JC; Keck, PE; Rhodes, LJ; Swann, AC; Hirschfeld, RM; Wozniak, PJ
  • Felbamate monotherapy has stimulant-like effects in patients with epilepsy.
    Ketter, TA; Malow, BA; Flamini, R; Ko, D; White, SR; Post, RM; Theodore, WH
  • The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.
    Petroff, OA; Rothman, DL; Behar, KL; Lamoureux, D; Mattson, RH
  • A summary of mechanistic hypotheses of gabapentin pharmacology.
    Taylor, CP; Gee, NS; Su, TZ; Kocsis, JD; Welty, DF; Brown, JP; Dooley, DJ; Boden, P; Singh, L
  • The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.
    Gee, NS; Brown, JP; Dissanayake, VU; Offord, J; Thurlow, R; Woodruff, GN
  • A placebo controlled evaluation of lamotrigine and gabapentin monotherapy in mood disorders.
    Frye, MA; Ketter, TA; Kimbrell, TA; Dunn, RT; Speer, AM; Osuch, EA; Luckenbaugh, DA; Corá-Locatelli, G; Leverich, GS; Post, RM
  • Gabapentin does not alter single-dose lithium pharmacokinetics.
    Frye, MA; Kimbrell, TA; Dunn, RT; Piscitelli, S; Grothe, D; Vanderham, E; Corá-Locatelli, G; Post, RM; Ketter, TA
  • Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus.
    Backonja, MM
  • Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial.
    Rowbotham, M; Harden, N; Stacey, B; Bernstein, P; Magnus-Miller, L
  • Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.
    Xie, X; Hagan, RM
  • The new antiepileptic drugs: A systematic review of their efficacy and tolerability.
    Marson, AG; Kadir, ZA; Hutton, JL; Chadwick, DW
  • Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management.
    Calabrese, JR; Sullivan, JR; Bowden, CL; Suppes, T; Goldberg, JF; Sachs, GS; Shelton, MD; Goodwin, FK; Frye, MA; Kusumakar, V
  • Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide.
    Warner, T; Patsalos, PN; Prevett, M; Elyas, AA; Duncan, JS
  • Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine.
    Malminiemi, K; Keranen, T; Kerttula, T; Moilanen, E; Ylitalo, P
  • Bidirectional interaction of valproate and lamotrigine in healthy subjects.
    Anderson, GD; Yau, MK; Gidal, BE; Harris, SJ; Levy, RH; Lai, AA; Wolf, KB; Wargin, WA; Dren, AT
  • Lamotrigine toxicity secondary to sertraline.
    Kaufman, KR; Gerner, R
  • (Lamictal 614 Study Group): A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder.
    Calabrese, JR; Suppes, T; Bowden, CL; Sachs, GS; Swann, AC; McElroy, SL; Kusumakar, V; Ascher, JA; Earl, NL; Greene, PL; Monaghan, ET
  • An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action.
    Shank, RP; Gardocki, JF; Streeter, AJ; Maryanoff, BE
  • Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold.
    White, HS; Brown, SD; Woodhead, JH; Skeen, GA; Wolf, HH
  • Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy.
    Petroff, OA; Hyder, F; Mattson, RH; Rothman, DL
  • Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER).
    Kanda, T; Kurokawa, M; Tamura, S; Nakamura, J; Ishii, A; Kuwana, Y; Serikawa, T; Yamada, J; Ishihara, K; Sasa, M
  • Topiramate: A review of preclinical, pharmacokinetic, and clinical data.
    Rosenfeld, WE
  • Bilateral angle-closure glaucoma and ciliary body swelling from topiramate.
    Rhee, DJ; Goldberg, MJ; Parrish, RK
  • Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
    Rosenfeld, WE; Doose, DR; Walker, SA; Nayak, RK
  • Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.
    Ben-Menachem, E; Henriksen, O; Dam, M; Mikkelsen, M; Schmidt, D; Reid, S; Reife, R; Kramer, L; Pledger, G; Karim, R
  • Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial.
    McElroy, SL; Arnold, LM; Shapira, NA; Keck, PE; Rosenthal, NR; Karim, MR; Kamin, M; Hudson, JI
  • A pilot study of topiramate as monotherapy in the treatment of acute mania.
    Calabrese, JR; Keck, PE; McElroy, SL; Shelton, MD
  • Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study.
    McIntyre, RS; Mancini, DA; McCann, S; Srinivasan, J; Sagman, D; Kennedy, SH
  • Basic mechanisms of gabitril (tiagabine) and future potential developments.
    Meldrum, BS; Chapman, AG
  • Adjunctive tiagabine treatment of psychiatric disorders: Three cases.
    Kaufman, KR
  • An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients.
    Schaffer, L; Schaffer, C; Howe, J
  • Tiagabine appears not to be efficacious in the treatment of acute mania.
    Grunze, H; Erfurth, A; Marcuse, A; Amann, B; Normann, C; Walden, J
  • Tiagabine and non-convulsive status epilepticus.
    Schapel, G; Chadwick, D
  • Studies with (Trileptal) oxcarbazepine in acute mania.
    Emrich, HM
  • Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.
    Friis, ML; Kristensen, O; Boas, J; Dalby, M; Deth, SH; Gram, L; Mikkelsen, M; Pedersen, B; Sabers, A; Worm-Petersen, J; Andersen, D; Jensen, PK
  • Clinical recommendations for oxcarbazepine.
    Smith, PE
  • Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance.
    Baruzzi, A; Albani, F; Riva, R
  • Absence of interaction between oxcarbazepine and erythromycin.
    Keranen, T; Jolkkonen, J; Jensen, PK; Menge, GP; Andersson, P
  • Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.
    Fattore, C; Cipolla, G; Gatti, G; Limido, GL; Sturm, Y; Bernasconi, C; Perucca, E
  • Zonisamide: A new antiepileptic drug.
    Oommen, KJ; Mathews, S
  • Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain.
    Mimaki, T; Suzuki, Y; Tagawa, T; Karasawa, T; Yabuuchi, H
  • Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode.
    Okada, M; Kawata, Y; Mizuno, K; Wada, K; Kondo, T; Kaneko, S
  • Zonisamide add-on for drug-resistant partial epilepsy.
    Chadwick, DW; Marson, AG
  • The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania.
    Kanba, S; Yagi, G; Kamijima, K; Suzuki, T; Tajima, O; Otaki, J; Arata, E; Koshikawa, H; Nibuya, M; Kinoshita, N; Asai, M
  • Levetiracetam.
    Nash, EM; Sangha, KS
  • Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents.
    Zona, C; Niespodziany, I; Marchetti, C; Klitgaard, H; Bernardi, G; Margineanu, DG
  • Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain.
    Fraser, CM; Sills, GJ; Forrest, G; Thompson, GG; Brodie, MJ
  • Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain.
    Sills, GJ; Leach, JP; Fraser, CM; Forrest, G; Patsalos, PN; Brodie, MJ
  • The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata.
    Loscher, W; Honack, D; Bloms-Funke, P
  • The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents.
    Rigo, JM; Hans, G; Nguyen, L; Rocher, V; Belachew, S; Malgrange, B; Leprince, P; Moonen, G; Selak, I; Matagne, A; Klitgaard, H
  • Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones.
    Poulain, P; Margineanu, DG
  • A systematic review of the safety profile of levetiracetam: A new antiepileptic drug.
    French, J; Edrich, P; Cramer, JA
  • Levetiracetam for acute mania.
    Goldberg, JF; Burdick, KE